Today, Caldwell Partners recognized CarbonCure’s CEO, Robert Niven as one of 2017’s Canada’s Top 40 Under 40.
Technology entrepreneurs in Cape Breton will soon have more support and a new place to collaborate and do business.
Aqualitas Inc. announced it is completing the build-out of 70,000 square feet of production space at its facility located in the Port Mersey Commercial Park in the Region of Queens Municipality.
Lockheed Martin partners with Metamaterial Technologies to support development of metaSOLAR, making its first solar investment in Canada.
Metamaterial Technologies Inc. (MTI) has signed a $5.6 million agreement with Lockheed Martin (NYSE: LMT), which represents Lockheed Martin’s first solar investment in Canada.
Marinvent Corporation and QRA Corp are pleased to announce the immediate availability of the integrated version of QRA’s QVscribe requirements tool with Marinvent's Synthesis certification tools.
Today CarbonCure Technologies (CarbonCure) announced the newest member of its growing team, concrete industry veteran, Jack Holley.
As vice president of concrete performance, Jack will be ensuring CarbonCure’s concrete producer customers maximize the environmental, production and cost benefits of CarbonCure’s technology.
QRA Corp, an emerging leader in design verification technology, announced that Carl Daniels has joined in the new role of vice president of business development. This acquisition comes on the heels of QRA’s February 2017 launch of QVscribe – QRA’s latest tool for analyzing requirements documents and finding vulnerabilities fast.
Nova Scotia researchers and early stage businesses are getting support to develop sustainable energy solutions, and bring them to market faster.
Energy Minister Michel Samson announced today, April 25, that seven projects are receiving funding from the Smart Energy Innovation Program, which was launched last fall.
Metamaterial Technologies Inc. (MTI), a smart materials and photonics company, announced today it has closed its institutional “Series A” equity financing worth $8.3 million led by Radar Capital Inc., with participation from Innovacorp and other investors.
Appili Therapeutics Inc. (Appili), an anti-infective drug development company, announced today it will be receiving an additional $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP), bringing IRAP support for this project to a total of up to $759,000.